Drugs in Dev. Dermatology
Phase I
Australia 
Lead Product(s) : Ruboxistaurin
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : DermBiont
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Acquisition of clinical-stage biotechnology company Chromaderm by DermBiont, will accelerate the development of Chromaderm’s drug candidate, ruboxistaurin (SM-030), topical formulation of the first and only targeted drug to treat skin hyperpigmentation...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 21, 2021
Lead Product(s) : Ruboxistaurin
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : DermBiont
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : PXS-6302
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmaxis Treatment to Prevent Wound and Burns Scars Clears Phase 1 Trial
Details : The phase 1 trial of the drug known as PXS-6302 tested 4 different strengths formulated as an easy to apply cream in 4 subjects as a single dose, scaling to the highest dose applied daily for 7 days in a further 6 subjects.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : PXS-6302
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BBI-4000 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hyperhidrosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 10, 2014
Lead Product(s) : Sofpironium Bromide
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Afamelanotide
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Afamelanotide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Vitiligo.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
September 08, 2011
Lead Product(s) : Afamelanotide
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
